Recent systematic reviews assessing the role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura (TTP) 1 , 2 identified two major observational studies describing relapse following rituximab treatment. One report described a significantly decreased frequency of relapse in 40 patients who were treated with rituximab within three days of diagnosis, in addition to plasma exchange (PEX) and high-dose corticosteroids, compared to historical control patients who had not received rituximab. 3 The other report compared 22 patients who were treated with rituximab for an inadequate response following initial treatment with PEX and corticosteroids to historical control patients who had not received rituximab; they reported no significant difference in relapse frequency related to rituximab treatment. 4 Both studies had important limitations. 1 Control patients were retrospectively selected from a time period preceding the patient group receiving rituximab. Some patients had a history of previous episodes of TTP. Not all patients had ADAMTS13 activity less than 10%. The frequency of corticosteroid use and other treatments for TTP was not controlled. A shorter duration of follow-up of rituximab-treated patients compared to control patients potentially biased the results to observe fewer relapses in the treatment group. We updated our previous systematic review 1 to February 23, 2016 and identified no additional comparable studies of rituximab treatment for TTP.
We report the experience of the Oklahoma TTP Registry with rituximab treatment for initial episodes of acquired TTP. The Registry is an inception Sixteen (43%) of the 37 surviving patients were treated with rituximab for their initial episode. Fourteen were treated because they were unresponsive to PEX and corticosteroids or they had recurrent thrombocytopenia when PEX was stopped. One patient was treated with rituximab because she could not return for evaluations. One patient was treated with rituximab (once) and For personal use only. on May 13, 2016. by guest www.bloodjournal.org From corticosteroids for a diagnosis of primary immune thrombocytopenia five days before TTP was diagnosed and PEX was begun; she then had three more weekly infusions. Fourteen of the 16 patients received four weekly infusions of 375 mg/m 2 . Two patients received only one infusion, one because she developed bacteremia and one because of no insurance.
Comparison of the 16 rituximab-treated patients to the 21 patients not treated with rituximab demonstrated no significant differences in demographic features, initial clinical data, or the year of their initial episode (Table) . The only differences were that rituximab-treated patients had more PEX treatments over a longer duration and received a greater total dose of corticosteroids, reflecting their inadequate response to initial treatment. Two of the 37 patients subsequently died, 16 and 30 months following TTP; neither were treated with rituximab for their TTP initial episode and neither had relapsed. Both deaths were related to systemic lupus erythematosus which preceded TTP.
The frequency of relapse among the rituximab-treated patients was significantly less than among patients not treated with rituximab (P = 0.009, Figure) . 6 Rituximab-treated patients relapsed at 2.5 and 9.9 years after their initial episode. Both patients had received four infusions of rituximab for their initial episode; they had ADAMTS13 activity less than 10% at the time of their relapse and they were re-treated with rituximab. Nine patients not treated with rituximab relapsed at 0.4-5.9 years (median, 3.1 years) after their initial For personal use only. on May 13, 2016. by guest www.bloodjournal.org From episode. Two of six patients who received rituximab for their initial relapses relapsed again after 3.0 and 8.6 years; they were again treated with rituximab.
One of three patients who had not received rituximab for their initial relapses relapsed again after 10 months; she was then treated with rituximab.
ADAMTS13 activity was less than 10% in 11 of 12 relapses; it was not measured in one. All 11 relapsing patients have survived.
Patients treated with rituximab for their initial TTP episode had significantly fewer relapses than patients not treated with rituximab, even though their initial episodes were complicated by inadequate response to initial treatment with PEX and corticosteroids. Compared to the previous reports, 3 , 4 our two groups of patients were concurrent. Only patients with their first episode of TTP were included. All patients had ADAMTS13 activity less than 10% at the time of their initial episodes. The patients' demographics, initial clinical data, and the durations of follow-up were not different. The greater total dose of corticosteroids given to rituximab-treated patients may have confounded our interpretation that rituximab was associated with the decreased frequency of relapses. Other limitations of our data are that there was no standard treatment protocol and only selected patients received rituximab. Although these patients were treated in nine different Oklahoma City hospitals, one of the authors (JNG) saw each of these 37 patients and participated in treatment decisions. 
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These data do not provide the strength of evidence of a randomized, controlled trial. However, since TTP is a rare disorder, it is unlikely that the effectiveness of rituximab will be studied in a randomized, controlled trial. The 
